Los Angeles, March 15, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, received a unanimous recommendation from the independent safety review committee (“SRC”) to continue clinical trial advancement of Trethera’s lead development asset, TRE-515, its first-in-class deoxycytidine […]
Los Angeles, February 15, 2023 — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Laurent Dubois to the Trethera Board of Directors as an independent director. A healthcare executive veteran with over two decades of […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2023-02-16 00:34:122023-02-16 00:34:12Trethera Announces Appointment of Laurent Dubois to Board of Directors
Los Angeles, January 24, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 8th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). Dr. Peter M. […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2023-01-24 01:47:292023-01-25 15:06:57Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Los Angeles, January 18, 2023 — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Boyd Quinnell, CPA, MBA, to the Trethera Board of Directors as an independent director. A veteran healthcare executive with over 30 […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2023-01-24 01:31:522023-01-24 01:35:35Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors
Los Angeles, October 19, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), has awarded Trethera a $1.6 million Fast-Track STTR […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2022-10-20 02:08:132022-10-20 02:13:38Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program
Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients
/in News /by TretheraLos Angeles, March 15, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, received a unanimous recommendation from the independent safety review committee (“SRC”) to continue clinical trial advancement of Trethera’s lead development asset, TRE-515, its first-in-class deoxycytidine […]
Trethera Announces Appointment of Laurent Dubois to Board of Directors
/in News /by TretheraLos Angeles, February 15, 2023 — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Laurent Dubois to the Trethera Board of Directors as an independent director. A healthcare executive veteran with over two decades of […]
Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
/in News /by TretheraLos Angeles, January 24, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 8th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). Dr. Peter M. […]
Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors
/in News /by TretheraLos Angeles, January 18, 2023 — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Boyd Quinnell, CPA, MBA, to the Trethera Board of Directors as an independent director. A veteran healthcare executive with over 30 […]
Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program
/in News /by TretheraLos Angeles, October 19, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), has awarded Trethera a $1.6 million Fast-Track STTR […]